首页 › 基金 › Opaleye Management Inc. › LYEL
Opaleye Management Inc. 对 LYEL 的持仓历史
LYELL IMMUNOPHARMA INC · 医疗保健
Opaleye Management Inc. 在 Q2 2026 的 13F 申报中披露持有 LYEL(LYELL IMMUNOPHARMA INC)344,025 股,市值约 US$4.8M,约占其申报组合的 0.44%,在其申报持仓中市值排名第 35 位。 Opaleye Management Inc. 最近 10 个申报季度中有 5 个季度披露了 LYEL 持仓,最早可追溯至 Q1 2024。
最后更新: 2026-10-24 · 来源: SEC EDGAR Form 13F-HR
Opaleye Management Inc. 对 LYEL 的持仓演变
Opaleye Management Inc. 于 Q1 2024 首次披露 LYEL 持仓:3,355,000 股(约 US$7.5M)。 在 5 次申报中,Opaleye Management Inc. 1 次增持、2 次减持、0 次保持不变。 最近一期申报(Q2 2026)显示持股 344,025 股、市值约 US$4.8M,环比增持 264,928 股。。 持仓曾出现大幅变动:Q2 2024 减持约 50% (随后一个季度股价下跌 5%)、Q2 2026 增持约 335% (随后一个季度股价下跌 30%)。
逐季持仓明细
| 季度 | 股数 | 金额 | 变化 |
|---|---|---|---|
| Q1 2024 | 3.35M | $7.48M | 新进 |
| Q2 2024 | 1.67M | $2.42M | 减持 |
| Q3 2024 | 1.40M | $1.93M | 减持 |
| Q1 2026 | 79.10K | $1.59M | 新进 |
| Q2 2026 | 344.02K | $4.83M | 增持 |
折线上的点按变动类型着色;缺失季度表示该季未申报持仓。
关于 LYEL 与 13F 数据
LYEL(LYELL IMMUNOPHARMA INC)属于医疗保健行业。我们追踪的基金中还有 31 只申报持有 LYEL,申报仓位最大的包括:ARCH Venture Management, LLC (US$45.5M), GSK plc (US$21.3M), Orland Properties Ltd (US$10.6M)。 根据美国 SEC 规定,管理资产超过 1 亿美元的机构投资者须在每季度结束后 45 天内提交 13F 表,披露其美股多头持仓。该数据不包含空头、大部分期权及海外持仓,因此应将其视为季度快照而非实时仓位。
其它持有 LYEL 的基金
- ARCH Venture Management, LLC 3.25M 股 · $45.53M · Q2 2026
- GSK plc 1.51M 股 · $21.25M · Q2 2026
- Orland Properties Ltd 754.70K 股 · $10.60M · Q2 2026
- Decheng Capital LLC 692.05K 股 · $9.72M · Q2 2026
- Almitas Capital LLC 581.41K 股 · $8.17M · Q2 2026
- Foresite Capital Management V, LLC 476.39K 股 · $6.69M · Q2 2026
- venBio Partners LLC 337.70K 股 · $4.74M · Q2 2026
- Alphabet Inc. 293.26K 股 · $4.12M · Q2 2026
- HSG Holding Ltd 152.30K 股 · $2.14M · Q2 2026
- Velan Capital Investment Management LP 105.00K 股 · $1.48M · Q2 2026
- MIC Capital Management UK LLP 87.03K 股 · $1.22M · Q2 2026
更多关于 Opaleye Management Inc.
常见问题
How long has Opaleye Management Inc. held LYEL?
Opaleye Management Inc. has disclosed LYEL holdings in 5 of the last 10 reported quarters, going back to Q1 2024.
What is Opaleye Management Inc.'s current position in LYEL?
As of Q2 2026, Opaleye Management Inc. holds 344.02K shares of LYEL (LYELL IMMUNOPHARMA INC), valued at $4.83M, representing 0.44% of its reported portfolio and ranking #35.
Has Opaleye Management Inc. been buying or selling LYEL?
In the latest 13F filing (Q2 2026), Opaleye Management Inc. increased its position in LYEL.
Which other funds hold LYEL?
Other major institutional holders of LYEL include ARCH Venture Management, LLC, GSK plc, Orland Properties Ltd, among 31 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.